


PHARMACEUTICAL 2020

Merus N.V. Rank 101 of 362







PHARMACEUTICAL 2020

Merus N.V. Rank 101 of 362



The relative strengths and weaknesses of Merus N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merus N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Merus N.V. is the variable Other Liabilities, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is -42%, being 261% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	247,368
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,787
Liabilities, Non-Current	3,872
Other Assets	12,293
Other Compr. Net Income	-1,308
Other Expenses	194
Other Liabilities	91,417
Other Net Income	0
Property and Equipment	3,715
Research and Development	55,680
Revenues	34,833
Selling, General and Administrative Expense	34,110

Output Variable	Value in 1000 USD
Assets	263,376
Liabilities	132,076
Expenses	89,984
Stockholders Equity	131,300
Net Income	-55,151
Comprehensive Net Income	-55,805
Economic Capital Ratio	-42%